…r an editorial see Schneider L. Lancet Neurol, epublished December 4, 2019 www.thelancet.com/action/showPdf?pii=S1474-4422%2819%2930480-6). Additional details were presented at the 12th Clinical Trials on Alzheimer’s Disease conference in San Diego in December, and reported by AlzForum (www.alzforum.org/news/conference-coverage/exposure-exposure-exposure-ctad-aducanumab-scientists-make-case). The median cumulative aducanumab exposure was 116 mg/kg…
…You are now leaving the NeuroSens website (www.neuro-sens.com). Lind Publishing Inc. accepts no responsibility for the content of linked sites. Click here if you wish to continue….
…sus interferon-β-1a (Kappos et al. ECTRIMS 2017; abstract P654). For added complexity, a composite disability measure was used to assess 24-week confirmed worsening on EDSS, Timed 25-Foot Walk (T25FW) or 9-hole Peg Test (9HPT). To be labelled as PIRA, there could be no relapse in the 30 days before or after the disability worsening. Since disability was evaluated every three months, there was a one-month window between disability assessments durin…
…in global sales in 2018 and was expected to earn over $4 billion in 2019 (www.roche.com/investors.htm). But it has not been all sunny days. A number of safety concerns have emerged with higher-efficacy DMTs. The FDA required a label change to Lemtrada in January following case reports of intracerebral hemorrhage (Rare cases of stroke reported with alemtuzumab, NeuroSens, December 14, 2018). Hypogammaglobulinemia has been reported in a subset of p…
…tem (FAERS) includes 1,669 PML cases in patients with MS (with and without comorbidities) for the period 2000-2019. A total of five cases of PML are listed for ocrelizumab, of which three mention no other DMT exposure. The database also lists seven PML cases treated with rituximab with no other DMT mentioned. However, it should be noted that on FAERS, PML may not have been confirmed and treatments may not be fully or accurately reported. FAERS als…
